Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with ...
SOUTHLAKE, Texas, April 24, 2025 /PRNewswire/ -- Renibus Therapeutics ® ("Renibus"), a clinical late-stage biopharmaceutical company focusing on the prevention and treatment of cardiac, renal, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback